CMT and BCVA before and at 1 week, 1 month, 2 months, 3 months after injection of intravitreal ziv-aflibercept (p value is measured against baseline values using the Wilcoxon signed-rank test)
| Baseline | 1 Week* | 1 Month | 2 Months | 3 Months | |
|---|---|---|---|---|---|
| Combined naïve and non-naïve cases | |||||
| Number of eyes | 30 | 22 | 29 | 26 | 22 |
| CMT mean±SD | 332.8±135.1 | 302.0±112.4 (p<0.001) | 244.8±77.3 (p<0.001) | 229.0±60.5 (p<0.001) | 208.2±50.91 (p<0.001) |
| BCVA logMAR±SD (range) | 1.08±0.67 (0.10–2.50) | 0.74±0.52 (0.04–2.00) (p=0.009) | 0.72±0.47 (0.00–1.60) (p <0.001) | 0.66±0.50 (0.00–1.60) (p=0.001) | 0.71±0.54 (0.00–2.00) (p=0.002) |
| Treatment-naïve eyes | |||||
| Number of eyes | 11 | 10 | 11 | 10 | 9 |
| CMT mean±SD | 415.5±144.6 | 345.2±114.3 (p=0.138) | 301.5±86.2 (p=0.021) | 254.3±73.4 (p=0.013) | 212.7±51.0 (p=0.008) |
| BCVA logMAR±SD (range) | 1.38±0.57 (0.54–2.50) | 0.76±0.59 (0.04–2.00) (p=0.005) | 0.82±0.50 (0.30–1.60) (p=0.005) | 0.78±0.58 (0.18–1.60) (p=0.005) | 0.68±0.46 (0.00–1.60) (p=0.008) |
*Eight subjects missed the 1-week follow-up. On the other side, a different set of eight subjects did not complete the 3-month follow-up.
BCVA, best-corrected visual acuity; CMT, central macular thickness.